ArticleInternational journal of clinical and experimental medicine2015
Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Pooled it
- Rauwolfia polysaccharide can inhibit the progress of ulcerative colitis through NOS2-mediated JAK2/STAT3 pathway.PloS one · 2024Article
- The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD.Journal of the Canadian Association of Gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the effects of 5-amino salicylic acids (5-ASAs) on the incidence rates of inflammatory bowel disease (IBD)-associated colonic cancer (IBDACa) and colonic dysplasia (IBDADys), as well as to evaluate the chemopreventive effects of 5-ASAs on IBDACa/Dys.
methodsSearches for officially published clinical studies on the effects of 5-ASAs on the chemoprevention of IBDACa/Dys were conducted in both foreign-language databases, including PubMed (Medline), EMCC, OVID, and the Cochrane Library, and Chinese databases, including Wanfang, Weipu (VIP), and CNKI, as well as using Google Scholar. For literature matching the selection criteria, the statistical software RevMan was employed to calculate odds ratio (OR) values and 95% confidence intervals (CIs). Sub-group analysis was performed for different study design types and IBD types.
resultsA total of fourteen papers were included in this study. The results of the analysis showed that compared with patients not using 5-ASAs, patients using 5-ASAs showed only 49% of the occurrence rate of IBDACa and IBDADys, OR = 0.49 (95% CI: 0.33-0.73). The OR of ulcerative colitis (UC) patients using 5-ASAs exhibiting UCCa/Dys was 0.44 (95% CI: 0.26-0.76).
conclusionThe use of 5-ASAs exerts a chemopreventive effect against IBDACa/Dys.
Indexed as
Identifiers
25932153PMC4402800W2398028118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.